Haha. You're funny.based on my discussions with Simon him and the team are working hard and establishing connections and having meetings for partnership purposes. Unfortunately this isn't a biotech with things in the pipeline curing diseases. It's a stock that most likely will move on revenue and material news.
News 
Market Data 
Discover 
